Modus Therapeutics Holding AB (MODTX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.552x

Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has a cash flow conversion efficiency ratio of -0.552x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.00 Million ≈ $-538.40K USD) by net assets (Skr9.07 Million ≈ $976.18K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Modus Therapeutics Holding AB to measure how much of total assets are equity-financed.

Modus Therapeutics Holding AB - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Modus Therapeutics Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Modus Therapeutics Holding AB debt service capacity to assess how comfortably operating cash covers total debt obligations.

Modus Therapeutics Holding AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Modus Therapeutics Holding AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Clever Group Corp VN:ADG	N/A
Agri-Tech (India) Limited NSE:AGRITECH	-0.010x
Abrdn Asia Focus PLC LSE:AAS	0.004x
Resources & Energy Group Ltd AU:REZ	-0.115x
Lanakam S.A AT:LANAC	0.007x
Redsense Medical AB ST:REDS	-0.053x
Traws Pharma Inc NASDAQ:TRAW	0.485x
JPMorgan Euro Small Companies Trust Plc LSE:JEDT	0.026x

Annual Cash Flow Conversion Efficiency for Modus Therapeutics Holding AB (2018–2025)

The table below shows the annual cash flow conversion efficiency of Modus Therapeutics Holding AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Modus Therapeutics Holding AB (MODTX) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr9.07 Million ≈ $976.18K	Skr-18.07 Million ≈ $-1.95 Million	-1.993x	+71.00%
2024-12-31	Skr2.14 Million ≈ $229.98K	Skr-14.68 Million ≈ $-1.58 Million	-6.870x	-628.09%
2023-12-31	Skr17.68 Million ≈ $1.90 Million	Skr-16.68 Million ≈ $-1.80 Million	-0.944x	-111.23%
2022-12-31	Skr-2.58 Million ≈ $-278.19K	Skr-21.72 Million ≈ $-2.34 Million	8.404x	+922.46%
2021-12-31	Skr15.73 Million ≈ $1.69 Million	Skr-16.08 Million ≈ $-1.73 Million	-1.022x	+1.16%
2020-12-31	Skr7.00 Million ≈ $752.77K	Skr-7.23 Million ≈ $-778.17K	-1.034x	-106.33%
2019-12-31	Skr-2.69 Million ≈ $-289.06K	Skr-43.90 Million ≈ $-4.72 Million	16.343x	+1075.08%
2018-12-31	Skr23.90 Million ≈ $2.57 Million	Skr-40.06 Million ≈ $-4.31 Million	-1.676x	--

About Modus Therapeutics Holding AB

ST:MODTX Sweden Biotechnology

Market Cap

$7.19 Million

Skr66.79 Million SEK

Market Cap Rank

#27803 Global

#615 in Sweden

Share Price

Skr0.38

Change (1 day)

+2.98%

52-Week Range

Skr0.27 - Skr3.83

All Time High

Skr6.80